{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:35:24Z","timestamp":1772325324196,"version":"3.50.1"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.8055","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T22:08:09Z","timestamp":1497478089000},"page":"1563-1567","source":"Crossref","is-referenced-by-count":10,"title":["Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy"],"prefix":"10.2169","volume":"56","author":[{"given":"Kyohei","family":"Kaburaki","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Toho University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Sugino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Toho University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneyuki","family":"Sekiya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Toho University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Toho University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoshi","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Toho University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Toho University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183, 1976.","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"2","unstructured":"2. Sylvester RJ, Van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970, 2002."},{"key":"3","unstructured":"3. Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Cenito-Urinary Cancers Group randomized phase 3 years of comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65: 69-76, 2014."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596-600, 1992.","DOI":"10.1016\/S0022-5347(17)37316-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. P\u00e9rez-Jacoiste As\u00edn MA, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, et al. Bacillus Calmette-Guerin (BCG) infection following intaravesical BCG administration as adjunctive therapy for bladder cancer. Incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine 93: 236-254, 2014.","DOI":"10.1097\/MD.0000000000000119"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of Bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. CID 36: 140-148, 2003.","DOI":"10.1086\/344908"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Elkabani M, Greene JN, Vincent AL. Disseminated <i>Mycobacterium bovis<\/i> after intravesicular bacillus Calmette-Guerin treatments for bladder cancer. Cancer Control 7: 476-481, 2000.","DOI":"10.1177\/107327480000700512"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jasmer RM, McCowin MJ, Webb WR, et al. Miliary lung disease after intravesical bacillus Calmette-Guerin immunotherapy. Radiology 201: 43-46, 1996.","DOI":"10.1148\/radiology.201.1.8816518"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Iantorno R, Nicolai M, Storto LM, et al. Miliary tuberculosis of the lung in a patient treated with bacillus calmette-guerin for superficial bladder cancer. J Urol 159: 1639-1640.","DOI":"10.1097\/00005392-199805000-00063"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nadasy KA, Patel RS, Emmett M, et al. Four cases of disseminated <i>Mycobacterium bovis<\/i> infection following intravesical BCG instillation for treatment of bladder carcinoma. South Med J 101: 91-95, 2008.","DOI":"10.1097\/SMJ.0b013e31815d4047"},{"key":"11","unstructured":"11. Colmenero JD, Sanjuan-Jimenez R, Ramos B, et al. Miliary pulmonary tuberculosis following intravesical BCG therapy: case report and literature review. Diagn Microbiol Infect Dis 74: 70-72, 2012."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Choi C-HR, Lee SO, Smith G. Subclinical military mycobacterium bovis following BCG immunotherapy for transitional cell carcinoma of the bladder. BMJ Case Rep, 2014 (Epub ahead of print).","DOI":"10.1136\/bcr-2013-201202"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Venn RM, Sharma N. Resolution without treatment of granulomatous pneumonitis due to intravesical BCG for bladder carcinoma. BMJ Case Rep, 2014 (Epub ahead of print).","DOI":"10.1136\/bcr-2014-204440"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Chang H, Klein JS, Norotsky M, et al. Granulomatous chest disease following intravesical Bacillus Calmette-Guerin immunotherapy. J Thorac Imaging 19: 60-62, 2004.","DOI":"10.1097\/00005382-200401000-00013"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/12\/56_56.8055\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T03:04:48Z","timestamp":1569467088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/12\/56_56.8055\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.8055","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}